perpetuity. It is made available under a CC-BY-NC 4.0 International license .

# Temporal Trends in Antibiotic Resistance in Europe, 1998-2019

Martin Emons<sup>1,2</sup>, François Blanquart<sup>\*3</sup>, Sonja Lehtinen<sup>\*1</sup>

#### October 2022

<sup>5</sup> <sup>1</sup> Department of Environmental System Science, Institute for Integrative Biology, ETH Zürich,

<sup>6</sup> Zürich, Switzerland

3

<sup>7</sup> <sup>2</sup> Department of Molecular Life Sciences, University of Zurich and Swiss Institute of Bioinfor <sup>8</sup> matics, Zürich, Switzerland

<sup>9</sup> <sup>3</sup> Center for Interdisciplinary Research in Biology, CNRS, Collège de France, PSL Research

<sup>10</sup> University, 75005 Paris, France

<sup>11</sup> \* joint last authors

## 12 Abstract

The emergence of resistant phenotypes following the introduction of new antibiotics is well doc-13 umented. However, the subsequent dynamics of resistance frequencies over long time periods 14 are less well understood: the extent to which resistance frequencies increase, the rate at which 15 resistance frequencies change, and how this depends on antibiotic consumption remain open 16 questions. Here, we systematically analyse the resistance trajectories emerging from 3.375,774 17 hospital bacterial isolates sampled from infections in Europe over 1998-2019, representing 887 18 bug-drug-country combinations. Our analyses support a model in which, after an initial in-19 crease, resistance frequencies reach a stable intermediate equilibrium. The plurality (37%) of 20 analysed trajectories were best described as 'stable' (neither increasing nor decreasing). The 21 second largest category of trajectories (21%) was those best described as 'stabilising' – i.e. 22 showing a transition from increasing frequency to a stable plateau. The antibiotic consumption 23 24 in a country predicts both the equilibrium frequency of the corresponding resistance and the speed at which this equilibrium is reached. Moreover, we find weak evidence that temporal 25 fluctuations in resistance frequency are driven by temporal fluctuations in hospital antibiotic 26 consumption. Overall, our results indicate that ever increasing antibiotic resistance frequencies 27 are not inevitable and that antibiotic management limits resistance spread. A large fraction of 28 the variability in the speed of increase and the equilibrium level of resistance remains unexplained 29 by antibiotic use, suggesting other factors also drive resistance dynamics. 30

## **1** Introduction

Antibiotic resistance is a serious public health concern, with an estimated 5 million resistance-32 associated deaths per year globally [1]. The emergence of resistance phenotypes following the 33 introduction of new antibiotics is well documented [2]. However, once present, the fate of 34 these resistance phenotypes - i.e. the change in the frequency of resistance in the population 35 over longer time frames – is less well understood. Existing studies into temporal trends in 36 resistance frequencies, often focused on specific species-antibiotic ('bug-drug') combinations, 37 report a variety of resistance trajectories – including increasing, decreasing, apparently stable, 38 and non-monotonic time courses [3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14]. A recent study looking 39 at 13 bug-drug combinations across a large number of countries also reported a mixture of 40 increasing and decreasing trends [15]. 41

<sup>42</sup> Beyond characterising overall trends, analysis of temporal trajectories has the potential to pro-

43 vide important additional insights into resistance dynamics. Predictions about medium to long-

<sup>44</sup> term resistance trends require an understanding of both the *speed* at which resistance frequencies

change and how this speed itself changes – e.g. is there evidence of the rate of resistance increase **NOTE:** This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. 46 slowing down as resistance frequencies get higher? In other words, if antibiotic consumption

perpetuity. It is made available under a CC-BY-NC 4.0 International license .

- <sup>47</sup> rates remain relatively stable, are resistance frequencies expected to continue rising to eventually
- <sup>48</sup> reach 100% ('fixation') or will we observe stabilisation at intermediate frequencies?

This question of fixation is particularly important as it informs long-term expectations about 49 the burden of resistance and has received considerable attention in the theoretical literature. An 50 intuitive understanding of resistance evolution suggests that fixation should occur if resistance 51 is beneficial enough to emerge in the first place. The simplest models of resistance dynamics 52 predict a logistic rise in resistance frequencies (Figure 1B), at a rate dependent on the population 53 antibiotic consumption and fitness cost associated with resistance [16]. For example, under 54 typical simplifying assumptions [16], if a population is prescribed an average of one course of 55 antibiotics per person per year and if resistance has little cost, the growth advantage of resistance 56 (called 'selection coefficient' in evolutionary biology) is of 1 per year. This is enough to shift 57 the frequency of resistance from 1% to 99% in 9 years. A higher cost of resistance leads to a 58 slower increase, but fixation is still expected – provided the cost is not so high that it outweighs 59 the benefit of resistance, in which case resistance would not emerge in the first place. These 60 intuitions also hold for many more complex models of resistance. 61

62 However, while some resistance trajectories (e.g. penicillin resistance in *Staphylococcus aureus* [4]) have indeed reached fixation, this is not the norm. An alternative model therefore suggests 63 the presence of 'balancing selection' (sometimes also called 'negative frequency-dependent selec-64 tion') which acts to stabilise resistance frequencies at intermediate levels. Multiple mechanistic 65 models may generate balancing selection, with stabilising mechanisms arising for example from 66 host population structure [17, 18, 19], strain structure [20] or within-host dynamics [21]. Yet, 67 the lack of observed fixation is not in itself evidence of stabilisation: trajectories could still be 68 rising towards 100%. It is therefore important to systematically assess evidence of stabilisation 69 - i.e. a rising phase in resistance followed by a plateau - in temporal trajectories across a range 70 of bug-drug combinations. 71

Resistance trajectories also matter for understanding the relationship between antibiotic con-72 sumption and resistance. Antibiotic consumption correlates with resistance frequencies across 73 European countries and US states [22, 23]. Under the fixation model, this correlation arises be-74 cause antibiotic consumption affects the *rate* at which resistance increases (Figure 1B,C). On the 75 other hand, under the balancing selection model, the correlation between antibiotic consumption 76 and resistance may arise not only because consumption affects the rate of increase in the rising 77 ('non-equilibrium') phase, but also because consumption affects the equilibrium frequency of re-78 sistance (Figure 1E,F). This distinction matters for predicting the impact of reducing antibiotic 79 consumption. Under the balancing selection model, if resistance is at equilibrium, reduction in 80 antibiotic consumption would lead to a lower plateau. Under non-equilibrium dynamics however, 81 a reduction in antibiotic consumption would either slow or reverse the rise in resistance. 82

Here we analyse a large number of bacterial isolates sampled from infections in Europe, collected 83 by the European Centre for Disease Control and Prevention (ECDC), together with antibiotic 84 consumption data. We provide a quantitative and systematic view of the temporal trends in 85 resistance and their relation to antibiotic consumption. Firstly, we provide an overview of speed 86 and direction of resistance dynamics and assess evidence for stabilisation. Secondly, we quantify 87 the association between antibiotic consumption and i) the equilibrium frequency of resistance 88 and ii) the speed of increase of resistance. Thirdly, we explore the correlation between year-89 on-year variation in antibiotic use and resistance. We thus provide a comprehensive picture of 90 antibiotic resistance evolution in Europe over the past two decades. 91

## 92 2 Results

#### <sup>93</sup> 2.1 Resistance is not systematically increasing and dynamics are slow

We used data from the European Center for Disease Prevention and Control (ECDC) to systematically investigate resistance trajectories in Europe from 1998 to 2019. In brief, the dataset consists of bacterial isolates tested for antibiotic resistance, with data for 8 species (*Streptococcus pneumoniae, Staphylococcus aureus, Enterococcus faecalis, Enterococcus faecium, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa*, and *Acinetobacter* spp.), 30 countries and af antibiotics. Following data cleaning steps that filtered out trajectories with insufficient sample size, the dataset retained for analysis consisted of 887 bug-drug-country combinations (see

<sup>101</sup> Methods for full details).

medRxiv preprint doi: https://doi.org/10.1101/2023.09.27.23296241; this version posted September 28, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.



Figure 1: Schematic of constant selection (A, B, C) and balancing selection (D, E, F) models of resistance dynamics. The different colours represent different strengths of selection pressure. For balancing selection, we arbitrarily chose a linearly declining selection coefficient. B and E show the predicted trajectories for each of the models. The frequency dynamics are generally linked with the selection coefficient by the differential equation,  $\dot{l_p} = s(l_p)$  where  $l_p$  denotes the logit-transformed frequency of resistance  $(\ln[p/(1-p)])$ , with p representing the frequency of resistance) and  $s(l_p)$  is the selection coefficient. A simple epidemiological model predicts a constant selection coefficient (A) equal to the antibiotic consumption rate minus the cost of antibiotic resistance [16]. This gives rise to a logistic trend to fixation (B). In contrast, balancing selection, but no clear consensus has been reached on a definitive model. C, F: Both models generate a positive correlation between antibiotic consumption and the frequency (here at time 50, materialised by points on B, E) and maximum slope of resistance increase (crosses on B, E).

For an overview of the temporal trends in resistance, we began by fitting a standard logistic 102 model to each trajectory. Overall, increasing trajectories are more common than decreasing 103 ones, with 62% rising vs 38% declining. However, for most trajectories, the temporal trend is 104 not statistically significant at the 0.05 level: 29% of all trajectories are significantly rising and 105 16% significantly declining (see Figure 2). The median slope – i.e. selection coefficient in the 106 fixation model of resistance – is 0.056 per year for the rising trajectories (-0.051 for the declining 107 trajectories). In the fixation model of resistance, this translates to an increase from 1% to 99%108 resistance in 165 years. 109

#### 110 2.2 Evidence of stabilising resistance frequencies

In order to test whether resistance trajectories might be stabilising at an intermediate plateau, we fitted two further models to each trajectory (see Methods for details and SI Figure 1): a scaled logistic model, in which the frequency is increasing towards an intermediate plateau rather than fixation, and a flat straight line with slope 0. Note that 10% of trajectories were not well characterised by any of the models and were removed from further analysis. After exclusion of these, the best model generally fit the data well (Figure 3).

We then compared the fits of the standard logistic (2 parameters), the scaled logistic (3 parameters) and flat line (1 parameter) models using the corrected Akaike Information Criterion (AICc). Trajectories best characterised by the plateauing logistic were categorised as 'stabilising' (21%) and those best characterised by the flat line as 'stable' (37%). The trajectories best characterised by the standard logistic model were further divided into 'increasing (s)' (17%), 'increasing (ns)' (4%), 'decreasing (ns)' (4%) and 'decreasing (s)' (17%) categories, where 's'

perpetuity. It is made available under a CC-BY-NC 4.0 International license .



Figure 2: The speed of increase or decrease in European resistance frequencies, as measured by the slope parameter in a standard logistic model, for all bug-drug-country combinations. For clarity, 6 combinations with very high or low slopes (outside of the interval [-1.75;1.75]) have been excluded (see Supporting Information). The plot includes both in- and outpatients. The 95% confidence intervals assume normality.

<sup>123</sup> and 'ns' denote statistical significance and non-significance at the 0.05 level.

Overall, these results suggest that resistance frequencies have indeed stabilised for many bugdrug combinations (Figure 4): a large proportion of the trajectories which appeared to be increasing in the standard logistic model are now classified as 'stable' or 'stabilising'. This is particularly striking for the species *E. coli* and *K. pneumoniae*. It is worth noting that the stabilising trends give more support to the balancing selection model than the stable trends, because the transition from increasing to stable resistance is observed for these trajectories.

To further understand the role of species, country and antibiotic class as determinants of observed temporal trends, we performed a regression analysis (SI Section 2) to correct for correlations among predictors (e.g. some species being more frequently sampled in some countries). The results (SI Figures 2 and 3) are consistent with the information conveyed in Figure 4.

Finally, to gain further insight into the dynamics of the increasing trajectories, we compared 134 the rate at which resistance is rising for the 'increasing (s)' category and for the non-equilibrium 135 phase of the 'stabilising' category. If the 'increasing' trajectories also reflect non-equilibrium 136 dynamics, we would expect these rates to be similar. We quantified the speed of increase 137 for each trajectory as the maximal rate of increase in the time frame for which we had data 138 (Methods 4.4, SI Figure 4). The fastest rates of increase were in the 'increasing (s)' category. 139 On the other hand, the mean rate of increase was significantly lower for the 'increasing (s)' than 140 the 'stabilising' category (2.2 vs 3.9 percentage points per year,  $p = 4.7 \times 10^{-4}$  in an linear 141 regression model with 'stabilising' vs 'increasing (s)' as a predictor of the speed of increase, n 142 = 299). This difference does not arise from confounding, as the effect remains significant in an 143 adjusted model ( $p = 1.9 \times 10^{-6}$  in a linear regression model with species, country and antibiotic 144 class as additional covariates). Thus while some of the increasing trajectories likely reflect 145 genuine non-equilibrium dynamics, the slow rate of change suggests some of these trajectories 146 may instead represent resistance frequencies responding to a changing selection pressure - due 147 to, for example, increasing antibiotic consumption (see SI Section 3 for caveats). 148

medRxiv preprint doi: https://doi.org/10.1101/2023.09.27.23296241; this version posted September 28, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .





Figure 3: Example trajectories of antibiotic resistance illustrating the different categories. One example (a specific country, bug-drug combination) is shown for each category in the eight panels. The last panels shows the distribution of errors for each category, for all country-bugdrug combinations. Error is quantified as the mean of the absolute value of the deviation between model predicted and actual resistance frequency, and trajectories with poor fit (i.e. error above 0.05) are excluded from further analysis.

#### 2.3Consumption of antibiotics predicts the level of stabilisation and 149 the rate of increase of antibiotic resistance 150

Next, we investigated which properties of the temporal trajectories of antibiotic resistance are 151 predicted by antibiotic use. We correlated both the plateau and maximum rate of increase of 152 the resistance trajectories with the use of the corresponding antibiotic class across countries, for 153 bug-drug combinations for which at least five countries had data (Methods). 154

First, we observed a positive correlation between the *plateau* level of resistance in the 'stable' 155 and 'stabilising' trajectories, and the consumption of the corresponding class of antibiotics in 156 the community for most bug-drug combinations (Figure 5A). Overall, the mean correlation was 157 significantly greater than 0 (mean correlation = 0.329 [0.18 - 0.48], N = 40 combinations, t-test 158  $p = 5.2 \times 10^{-5}$ ) and several individual correlations were significantly different from zero, despite 159 considerable uncertainty in each correlation coefficient. This also held true when considering 160 antibiotic use in the hospital instead of in the community (SI Figure 5); mean correlation 161 = 0.322 [0.17 - 0.48], N = 31 combinations, t-test  $p = 1.7 \times 10^{-4}$ ). This is consistent with 162 selection by antibiotics increasing the plateau level of resistance. 163

Second, the rate of increase of resistance frequency for the 'stabilising' and 'significantly in-164

medRxiv preprint doi: https://doi.org/10.1101/2023.09.27.23296241; this version posted September 28, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .



Figure 4: Proportion of trajectories falling into each temporal trend category, by species (A), country (B) and antibiotic class (C). The numbers give the actual sample size of trajectories in each category. This figure does not correct for correlations among the categories (e.g. some species being more frequently sampled in some countries). A corrected analysis is presented in SI Section 2 and is consistent with the information presented here.

creasing' trajectories also exhibited a correlation with antibiotic use, but the signal was weaker 165 than for the plateau. In this analysis, the rate of increase was computed as the maximal slope 166 reached over the time-period in which we had resistance data. The individual correlations could 167 be either negative or positive and none were individually significantly different from 0 (Fig-168 ure 5B). However, overall, the set of correlations had a mean significantly greater than 0 (mean 169 correlation = 0.18 [0.06; 0.30], N = 14 combinations, t-test p = 0.005). The mean was similar 170 when considering antibiotic use in the hospital sector, though not significantly different from 171 0 (mean correlation = 0.19 [-0.08; 0.45], N = 10 combinations, t-test p = 0.15) (SI Figure 5). 172 When restricting to stabilising trajectories only, we obtained very few bug-drug combinations, 173 most of them from *E. coli* and showing a positive correlation (SI Figure 6). All in all, there 174 was evidence that the rate of increase in antibiotic resistance is driven by antibiotic use. 175

Lastly, if we ignore temporal trends, the median level of resistance over time was also generally positively correlated with consumption (SI Figure 7).

# Antibiotic use as a predictor of temporal variation in antibiotic resistance

Following the earlier result that 'increasing' trajectories may reflect a changing equilibrium 180 frequency, we investigated whether year-to-year variation in antibiotic use could cause corre-181 sponding year-to-year fluctuations in the level of resistance. For each country, we computed 182 the temporal correlation of resistance with use of the corresponding antibiotic, for combinations 183 for which we had at least five years of data and for all categories of temporal trajectory. We 184 then averaged these temporal correlations over all countries and retained only bug-drug combi-185 nations for which we had at least five countries. There was overall a positive mean correlation 186 187 between resistance and antibiotic use in the hospital sector (mean correlation = 0.06 [0.03; 0.09],

medRxiv preprint doi: https://doi.org/10.1101/2023.09.27.23296241; this version posted September 28, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .





Figure 5: Spatial correlation coefficients between (A) the plateau frequency of antibiotic resistance, or (B) rate of increase, and the rate of use of the corresponding antibiotic in the community, for all bug-drug combinations. The number of countries included is indicated for each combination. The vertical dashed lines show the overall mean. Trends are similar when considering hospital instead of community use (SI Figure 5).



Figure 6: Temporal variation in hospital antibiotic use as a predictor of temporal variation in antibiotic resistance. (A), the temporal correlation of the frequency of resistance with hospital antibiotic use across bug-drug combinations. The number of countries included is indicated for each combination. The vertical dashed lines show the overall mean. (B), the distribution of temporal trends in antibiotic consumption in hospitals for each category of trend in resistance.

N = 63 combinations, t-test  $p = 6.8 \times 10^{-4}$ ) (Figure 6A), but this was not true when considering 188 the use of antibiotics in the community sector (mean correlation = 0.01 [-0.02; 0.04], N = 65189 combinations, t-test p = 0.6) (SI Figure 8). 190

Because of the mixed evidence, to further investigate the possibility that the frequency of resis-191 tance follows the fluctuations in antibiotic use, we computed two additional partially independent 192 indicators (SI Figure 9) [24]. These also suggested that antibiotic resistance follows temporal 193 fluctuations in the use of antibiotics in the hospital sector, but not in the community. 194

We last looked at whether sustained trends in antibiotic consumption (computed as the Spear-195

perpetuity. It is made available under a CC-BY-NC 4.0 International license .

man correlation between calendar year and consumption level) predict the temporal trajectory 196 of antibiotic resistance. In other words, we tested whether increasing/decreasing resistance tra-197 jectories are associated with increasing/decreasing consumption of the corresponding antibiotic 198 in the corresponding country. Hospital antibiotic consumption rate was increasing on average for 199 all resistance trends (Figure 6 B), but the increase in consumption was significantly higher for 200 the increasing (s and ns) than decreasing (s and ns) categories (Wilcox test, p = 0.002). Again, 201 no significant trend was found when considering community instead of hospital consumption 202 (Wilcox test, p = 0.14). 203 All in all these analyses provide some evidence that the frequency of antibiotic resistance follows 204

changes in the use of the antibiotic – either year-on-year fluctuations and/or sustained trends – in the hospital, but not community sector.

## 207 2.5 Case-study: few rising trajectories in previously high-consumption 208 countries

Finally, we combined the insights above to further understand specific resistance trends. Some of the countries with the smallest proportion of increasing trajectories (Figure 4 and SI Figure 2), such as Greece, Italy, and France, were also the countries with highest levels of antibiotic use in the community in the early 2000s [22]. Confirming this observation, there was overall a significant negative correlation between antibiotic use in the community sector in 2000 and the proportion of increasing resistance trajectories (SI Figure 10C). Such trend was not observed for hospital consumption.

We hypothesised two non-mutually exclusive explanations for this intriguing finding. One pos-216 sibility is that countries with high community antibiotic use in the early 2000s have taken 217 effective measures to halt the increase of antibiotic resistance. We looked at whether high 218 community antibiotic use in 2000 correlated with a decrease in total antibiotic consumption 219 during the study period. This was true in the hospital sector, but not in the community (SI 220 Figure 10A,B). Alternatively, as high antibiotic consumption leads to a faster rise in resistance, 221 trajectories in high consumption countries are more likely to have reached a plateau either be-222 fore or during the study period, while trajectories in lower consumption countries are still rising 223 towards the plateau. This hypothesis requires that increasing trajectories reflect, at least in 224 part, non-equilibrium dynamics. In support of this hypothesis, we found that countries with 225 high community antibiotic consumption in 2000 had a faster rate of increase in the rising phase 226 of the stabilising trajectories (Spearman's rho: 0.71, p = 0.0014). 227

## 228 3 Discussion

Our analysis of resistance trajectories in Europe suggests that antibiotic resistance frequencies 229 are not consistently increasing and instead often appear stable over two decades. This obser-230 vation has been previously discussed in the context of S. pneumoniae [17, 18, 20] and, to a 231 more limited extent, in other species [19]. Our work provides systematic evidence for stability 232 and - notably - stabilisation of resistance in eight important bacterial species. However, a non-233 negligible minority of trajectories were categorised as either significantly increasing (17%) or 234 significantly decreasing (17%). These trajectories could reflect either non-equilibrium dynamics 235 or a changing equilibrium frequency in response to changing antibiotic use. While we cannot 236 determine for certain which is the case for individual trajectories, our analysis suggests a mix 237 of these scenarios. 238

There was considerable variability in trends by bacterial species, country, and antibiotic class. 239 We were able to explain some of this variability. First, resistances were in part associated with 240 the rate of use of the corresponding antibiotic. In addition to previous work showing a spatial 241 correlation between median consumption and median resistance [22, 23], we evidenced the effect 242 of antibiotic consumption on both the rise and the stable level of resistance. We also investigated 243 the *temporal* correlation between antibiotic use and resistance frequency. Resistance was weakly 244 associated with hospital – but not community – antibiotic consumption, both in terms of year-245 on-year fluctuations and sustained trends. Second, the species E. coli and K. pneumoniae were 246 associated with a particularly large number of increasing or stabilising trajectories. This might 247 be linked to the emergence and spread of the CTX-M beta-lactamase enzyme in the late 1990s 248 and early 2000s [25]. Third, countries with high antibiotic consumption in 2000 [22] – e.g. Italy, 249 Greece and France – saw fewer increasing resistance trajectories than other countries. This was 250

perpetuity. It is made available under a CC-BY-NC 4.0 International license .

- <sup>251</sup> not straightforwardly explained by a decrease in antibiotic use, but might be explained by these
- <sup>252</sup> trajectories having stabilised earlier in these countries than in others.

A large part of the variability in resistance within and across countries remained unexplained. 253 One reason could be that differences in host population structure, and heterogeneity in antibiotic 254 consumption within this structure, can lead to different resistance frequencies for populations 255 with the same average consumption [19]. A second explanation is the spillover of resistance from 256 neighbouring countries: even small amounts of migration from other countries are sufficient to 257 influence local levels of resistance, which would tend to weaken the spatial correlation across 258 countries [18, 26]. Thirdly, the coupling of multiple resistance genes co-occurring on bacterial 259 strains ('linkage disequilibrium') [27] means that the frequency of resistance against a particular 260 antibiotic could be affected by the consumption of other antibiotics. Finally, a number of studies 261 have reported statistical associations between the frequency of resistance and other factors 262 e.g. temperature, pollution, governance- and infrastructure-related factors [15, 28, 29]. While 263 this strongly suggests selection pressure is not solely dependent on antibiotic consumption, 264 it is challenging to determine which factors are truly causal. Determining the causal role of 265 factors beyond average antibiotic consumption requires detailed epidemiological and genomic 266 data, including host metadata (host characteristics, geographic location), contact networks, 267 and sequence data conveying the genetic coupling between different resistances and other loci 268 determining important bacterial phenotypes. 269

One important limitation of our study is data quality and consistency across countries. The 270 tested isolates do not necessarily reflect a random sample of bacteria circulating in the human 271 population, or even of bacteria infecting hospital patients. For example, intensified testing 272 in the context of hospital outbreaks might cause the over-representation of particular clones 273 in a specific country and year. Resistance frequencies are not comparable across years if the 274 threshold for resistance is changed, as was the case in France for *P. aeruqinosa* [30]. The 275 antibiotic consumption data is subject to similar data quality considerations. To limit the 276 inclusion of biased or poor-quality data in our analyses, we did not consider the trajectories for 277 which none of our models fitted the data well ('poor fit' category), and we removed temporal 278 outliers from the consumption data. Despite these concerns, most trajectories were quite smooth 279 temporally (Figure 3). Furthermore, while potential biases will affect the overall estimate of 280 resistance frequency, as long as bias remains constant in time, they will not affect the detection 281 and categorisation of temporal trends. Although the data from the ECDC may represent one 282 of the largest and best standardised datasets on antibiotic resistance and consumption, it is 283 limited to European countries. It is important to determine whether the pattern of stability 284 and stabilising also holds elsewhere, particularly in low and middle income countries (LMICs). 285 While data sources covering a wider range of countries exist (e.g. ResistanceMap<sup>1</sup> and ATLAS<sup>2</sup>), 286 their temporal span is currently much smaller for LMICs than the two decades covered by the 287 European network. Thus, while quantifying overall resistance trends in LMICs is possible [15], 288 assessing evidence for stabilisation may prove more challenging. 289

Finally, the stability of resistance trends may not be robust to evolutionary innovation. With sustained selection pressure, bacteria may evolve new and less costly resistance mechanisms and compensatory mutations that alleviate the cost of resistance. This would result in the progressively increase the equilibrium level of resistance. While compensatory evolution is readily observed under laboratory conditions, its contribution to real-word resistance dynamics is unclear.

In conclusion, using antibiotic resistance data from 3,375,774 bacterial isolates from infections, 296 encompassing 8 bacterial species, 30 European countries, and 20 years, we reveal that resis-297 tance trajectories are for the most part stable or stabilising. This overall behaviour of antibiotic 298 resistance trajectories suggests that ever increasing antibiotic resistance is not inevitable and 299 that resistance management can be effective in limiting resistance spread. Observed resistance 300 dynamics were, to some extent, explainable by levels of antibiotic consumption. However, this 301 explanatory power was relatively low, highlighting important gaps in our understanding of resis-302 tance dynamics. All in all, we open perspectives for further work elucidating how the complex 303 ecology of bacteria determine the long-term fate of antibiotic resistance. 304

<sup>&</sup>lt;sup>1</sup>https://resistancemap.onehealthtrust.org/AntibioticResistance.php

 $<sup>^{2}</sup>$  https://atlas-surveillance.com

perpetuity. It is made available under a CC-BY-NC 4.0 International license .

## 305 Acknowledgements

FB is funded by ERC StG 949208 EvoComBac. SL is funded by the Swiss National Science Foundation (PR00P3\_201618).

Data from The European Surveillance System—TESSy, provided by Finland, Sweden, Belgium, 308 Germany, Greece, Ireland, Italy, Luxembourg, Netherlands, Norway, Portugal, United Kingdom, 309 Austria, Bulgaria, Czech Republic, Denmark, Estonia, Spain, Malta, Slovenia, France, Croatia, 310 Hungary, Poland, Slovakia, Romania Cyprus, Latvia, Lithuania and released by ECDC. The 311 views and opinions of the authors expressed herein do not necessarily state or reflect those 312 of ECDC. The accuracy of the authors' statistical analysis and the findings they report are 313 not the responsibility of ECDC. ECDC is not responsible for conclusions or opinions drawn 314 from the data provided. ECDC is not responsible for the correctness of the data and for data 315 management, data merging and data collation after provision of the data. ECDC shall not be 316 held liable for improper or incorrect use of the data. 317

perpetuity. It is made available under a CC-BY-NC 4.0 International license .

# 318 4 Methods

## 319 4.1 Data

#### 320 4.1.1 Resistance Raw Data

The data on the antimicrobial resistance rates are released by the European Surveillance System
TESSy, provided by Finland, Sweden, Belgium, Germany, Greece, Ireland, Italy, Luxembourg,
Netherlands, Norway, Portugal, United Kingdom, Austria, Bulgaria, Czech Republic, Denmark,
Estonia, Spain, Malta, Slovenia, France, Croatia, Hungary, Poland, Slovakia, Romania Cyprus,
Latvia, Lithuania and released by the European Centre for Disease Prevention and Control
(ECDC). The data covers the years 1998-2019.

The raw data, available upon request from the ECDC, is in case-based format, and consists of, for each isolate: the date of the isolation, the pathogen, the patient type (inpatient or outpatient), and the antimicrobial resistance level (sensitive, intermediate, resistant according to EUCAST clinical breakpoints) to various antibiotics. Outpatients consist of patients presenting at the hospital for dialysis, other day hospital care, or emergency. A more detailed description of the raw resistance data is made available by the ECDC [31].

#### 333 4.1.2 Antibiotic Consumption Raw Data

Data on antibiotic consumption is publicly available from the ECDC, and consists of defined 334 daily dose (DDD) per 1000 inhabitants by antibiotic class, country, year, sector (community, 335 hospital care, total care) and uptake route (oral, parenteral, rectal, inhalation, implant, all). 336 The dataset includes the same 30 countries as the resistance dataset, spans the years 1997-2016, 337 and consists of the following classes of antibiotics: J01A (tetracyclines), J01B (amphenicols), 338 J01C (penicillins), J01D (other betalactams), J01E (sulfonamides), J01F (macrolides), J01G 339 (aminoglycosides), J01M (quinolones), J01R (combinations of antibacterials), J01X (others), 340 P01A (agents against amoebiasis and other protozoal diseases), A07A (intestinal antiinfectives). 341 A detailed description of the consumption data is made available by the ECDC [32]. 342

## 343 4.2 Preprocessing

#### <sup>344</sup> 4.2.1 Processing of antibiotic resistance data

We computed the frequency of resistant for each bug, drug, country, year, and patient type combination. Intermediate isolates were considered resistant. We compared the temporal trends in resistance in inpatients and outpatients for drug-pathogen-country combinations that had data on both types of patients. The temporal trends in outpatients and in patients were very correlated, with similar or higher levels of resistance in inpatients. Therefore we only considered resistance measured in inpatients for further analyses.

medRxiv preprint doi: https://doi.org/10.1101/2023.09.27.232962 preprint (which was not certified by peer review) is the auth /10.1101/2023.09.27.23296241; this version posted September 28, 2023. The copyright holder for this d by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

- 351 4.2.2 List of the bug-drug combinations investigated:
- $_{\tt 352}$  S. aureus: CIP CLO DAP DIC FLC FOX LNZ LVX MET NOR OFX OXA RIF TEC
- 353 S. pneumoniae: AZM CIP CLR CRO CTX ERY LVX MFX NOR OFX OXA PEN
- 354 E. faecalis: AMP AMX GEH LNZ TEC VAN
- 355 E. faecium: AMP AMX GEH LNZ TEC VAN
- 356 E. coli: AMC AMK AMP AMX CAZ CIP COL CRO CTX DOR ETP FEP GEN IPM LVX MEM MFX NAL NET NOR OFX PIP POL TGC TOB TZP
- 357 K. pneumoniae: AMC AMK CAZ CIP COL CRO CTX DOR ETP FEP GEN IPM LVX MEM MFX NAL NET NOR OFX PIP POL TGC TOB TZP
- <sup>358</sup> *P. aeruginosa*: AMK CAZ CIP COL DOR ETP FEP GEN IPM LVX MEM NET PIP POL TOB TZP
- 359 Acinetobacter spp.: AMC AMK AMP AMX CAZ CIP COL CTX DOR FOX GEH GEN IPM LVX MEM NAL NET POL TOB TZP VAN

perpetuity. It is made available under a CC-BY-NC 4.0 International license .

#### <sup>360</sup> 4.2.3 Processing of antibiotic use data

For many countries and years, the total consumption of antibiotics by all routes of administration was reported. We primarily used this information when it was available. Moreover, some countries and years recorded the consumption decomposed by route of administration of antibiotics. This was most commonly oral and parenteral, and, less frequently, inhalation, rectal, implant, "other" routes. When total consumption was not available, we summed the consumption recorded over all routes to obtain an estimate of total consumption.

<sup>367</sup> We considered consumption both in the hospital sector and in the community.

To remove all outliers for a given antibiotic class, country, sector, route of administration for each combination we removed datapoints for years not within  $\pm 3 \times IQR$  (IQR = Inter quartile range) of the temporal median.

#### **4.3** Inferring temporal trends in antibiotic resistance

For combinations of bug, drug, country, we fitted logistic models to the temporal trends in the frequency of resistance. We only included the combinations with a time series of at least 5 years, where all years had at least 30 isolates tested for drug resistance, and in total at least 10 resistant bacterial isolates. Fitting was done with non-linear least square regression, with the function nlsLM from the minpack.lm R package, except for the flat line which was fit using Im from the base stats package [33, 34]. The error is assumed to be normally distributed and proportional to the inverse of the sample size for each year.

<sup>379</sup> We fitted three models to the temporal trends data:

1. A standard logistic model with two parameters, an offset and a slope. The standard logistic model results in an increasing sigmoid from 0 to 1, or a decreasing sigmoid from 1 to 0 if the slope is negative. This corresponds to the standard population genetics model describing the action of selection on resistance frequency. The resistance frequency f for year t under this model is given by:

$$f(t) = \frac{1}{1 + e^{-k_1(t-k_0)}} \tag{1}$$

where  $k_1$  is the slope parameter and  $k_0$  determines the offset.

2. A 'flat' model with slope 0 and an intercept. In this model, the resistance frequency f for year t is given by:

$$f(t) = k_2 \tag{2}$$

388 3. A plateauing logistic model with a maximum frequency below 1, where the sigmoid function 389 is scaled by parameter  $k_2$ . In this model, the resistance frequency f for year t is given by:

$$f(t) = \frac{k_2}{1 + e^{-k_1(t-k_0)}} \tag{3}$$

390

We compared the models using the corrected Akaike Information Criterion (AICc), with the best model corresponding to the smallest AICc [35]. The AICc is given by:

$$2k - 2\ln(\hat{L}) + \frac{2k^2 + 2k}{n - k - 1} \tag{4}$$

where  $\hat{L}$  is the maximum likelihood estimate, k the number of parameters and n the sample size.

We quantified the goodness of fit with the mean absolute error of the best fit model. For the two logistic models, we determined the statistical significance of the slope based on a threshold of p < 0.05.

- <sup>398</sup> This resulted in six categories of temporal trends:
- (i) significantly increasing, when the best model was the standard logistic and the slope was
   significantly positive.

#### perpetuity. It is made available under a CC-BY-NC 4.0 International license .

- (ii) non-significantly increasing, when the best model was the standard logistic and the slope
   was positive but not significantly different from 0
- (iii) non-significantly decreasing, when the best model was logistic and the slope was negative
   but not significantly different from 0.
- (iv) significantly decreasing, when the best model was logistic and the slope was significantly
   negative.
- $_{407}$  (v) stable, when the best model was a flat fit.
- (vi) stabilising, when the best model was the logistic with plateau different from 1.

Additionally, some trajectories were classified as 'poor fit' when the mean absolute error exceeded
0.05 and were not analysed further. The 'stabilising' category can be subdivided further in
'stabilising significantly increasing' and 'stabilising non-significantly increasing' depending on
the significance of the slope leading to the plateau.

#### 413 4.4 Comparison of rate of resistance change across models

The slope parameters in the standard and scaled logistic models  $(k_1 \text{ in Equations 1 and 3})$  are 414 not directly comparable. This is because the parameter reflects how quickly resistance will reach 415 its maximum level. As the maximum is different in the two models, the same slope parameter 416 in the two models translates to a different rate of change in the actual resistance frequencies. 417 For the analyses in which we sought to compare the speed of change across the two models 418 i.e. the comparison of increasing and stabilising trajectories and the correlation with antibiotic 419 usage – we computed a comparable measure of the change in resistance frequencies. Specifically, 420 we looked at the maximal rate of change observed in the temporal window for which we had 421 data. 422

#### 423 4.5 Correlation between antimicrobial consumption and resistance

We correlated antimicrobial consumption and resistance across countries and time. In all cases,
we correlated the level of resistance to a particular antibiotic to the total consumption of all
antibiotics of this class.

#### 427 4.5.1 Correlation between antimicrobial consumption and resistance across coun-428 tries

For each bug-drug combination, we correlated across countries the median antibiotic consump-429 tion across years, to three properties of the resistance temporal trends. These three properties 430 were the median resistance across years, the resistance plateau (for 'stable' and 'stabilising' 431 categories), the slope of the logistic (for 'logistic significantly increasing' and 'stabilising sig-432 nificantly increasing' categories). As described above, the slope was computed as the maximal 433 rate of change reached in the temporal window for which we had data This ensures the slope 434 is comparable across the logistic model with and without intermediate plateau, unlike the slope 435 parameter of the logistic. We quantified the correlation with Spearman's rank correlation coef-436 ficient across countries, for bug-drug combinations represented by at least five countries. The 437 correlation was calculated using SpearmanRho from DescTools version 0.99.49 [36]. 438

<sup>439</sup> This analysis resulted in a number of correlation coefficients. These coefficients are calculated
<sup>440</sup> for combinations of antibiotics prescribed in the community vs. the hospital sector, (we remind
<sup>441</sup> that we consider only resistance in inpatients), and of the three properties of temporal trends
<sup>442</sup> which are correlated (total of 6 combinations).

#### 443 4.5.2 Correlation between antimicrobial consumption and resistance across time

For each country-bug-drug combination, we correlated across years the level of resistance and level of antibiotic consumption. This results in a Spearman's rank correlation coefficient for the country-bug-drug combinations and each of the four combinations of community vs. hospital sector. This was again calculated using SpearmanRho from DescTools version 0.99.49 [36]. We kept only country-bug-drug combinations with at least 5 years of data available. We averaged these correlations over countries for each bug-drug combination, retaining only bug-drug combinations for which 5 countries of more were represented. It is expected that the temporal

perpetuity. It is made available under a CC-BY-NC 4.0 International license .

- 451 correlation between the frequency of resistance and the corresponding antibiotic use is positive
- <sup>452</sup> if the bacterial population adapts to the changing use of specific antibiotic.

We additionally computed a cross-temporal correlation, whereby the consumption data were 453 shifted by -1 and +1 year compared to the resistance data. To give additional indications that 454 yearly variation in antibiotic resistance follows variation in consumption, we used these cross-455 temporal correlations. First, if the bacterial population adapts closely to the contemporaneous 456 antibiotic use, it is expected that the "temporal adaptation" pattern formed by the cross-457 correlation for time-shifts -1, 0 and +1 is maximal at 0 [24]. We counted the fraction of 458 bug-drug combinations for which temporal adaptation was maximal at 0 and calculated the 459 probability of this fraction under a binomial model with true probability 0.25. Second, we 460 compared the temporal correlation with the spatial correlation across bug-drug combinations. 461 Indeed, if the bacterial population evolves in response to changing antibiotic use, it is expected 462 that levels of resistance match both the contemporaneous and local antibiotic use [24]. We 463 therefore tested whether bug-drug combinations with stronger spatial correlations also exhibited 464 stronger temporal correlations, by correlating the two correlations across bug-drug combinations 465 (Figure 9). 466

#### 467 4.6 Code Availability

<sup>468</sup> All code is available on the following GitHub repository:

469 https://github.com/mjemons/temporal-trends-AMR-manuscript

All analyses were performed with R version 4.2.3 [34]. Packages are managed with renv [37].

perpetuity. It is made available under a CC-BY-NC 4.0 International license .

## 472 **References**

- [1] Christopher JL Murray, Kevin Shunji Ikuta, Fablina Sharara, Lucien Swetschinski, 473 Gisela Robles Aguilar, Authia Gray, Chieh Han, Catherine Bisignano, Puja Rao, Eve Wool, 474 Sarah C. Johnson, Annie J. Browne, Michael Give Chipeta, Frederick Fell, Sean Hackett, 475 Georgina Haines-Woodhouse, Bahar H. Kashef Hamadani, Emmanuelle A. P. Kumaran, 476 Barney McManigal, Ramesh Agarwal, Samuel Akech, Samuel Albertson, John Amuasi, 477 Jason Andrews, Aleskandr Aravkin, Elizabeth Ashley, Freddie Bailey, Stephen Baker, Bud-478 dha Basnyat, Adrie Bekker, Rose Bender, Adhisivam Bethou, Julia Bielicki, Suppawat 479 Boonkasidecha, James Bukosia, Cristina Carvalheiro, Carlos Castañeda-Orjuela, Vilada 480 Chansamouth, Suman Chaurasia, Sara Chiurchiù, Fazle Chowdhury, Aislinn J. Cook, 481 Ben Cooper, Tim R. Cressey, Elia Criollo-Mora, Matthew Cunningham, Saffiatou Darboe, 482 Nicholas P. J. Day, Maia De Luca, Klara Dokova, Angela Dramowski, Susanna J. Dunachie, 483 Tim Eckmanns, Daniel Eibach, Amir Emami, Nicholas Feasey, Natasha Fisher-Pearson, 484 Karen Forrest, Denise Garrett, Petra Gastmeier, Ababi Zergaw Giref, Rachel Claire Greer, 485 Vikas Gupta, Sebastian Haller, Andrea Haselbeck, Simon I. Hay, Marianne Holm, Su-486 san Hopkins, Kenneth C. Iregbu, Jan Jacobs, Daniel Jarovsky, Fatemeh Javanmardi, 487 Meera Khorana, Niranjan Kissoon, Elsa Kobeissi, Tomislav Kostvanev, Fiorella Krapp, 488 Ralf Krumkamp, Ajay Kumar, Hmwe Hmwe Kyu, Cherry Lim, Direk Limmathurotsakul, 489 Michael James Loftus, Miles Lunn, Jianing Ma, Neema Mturi, Tatiana Munera-Huertas, Patrick Musicha, Marisa Marcia Mussi-Pinhata, Tomoka Nakamura, Ruchi Nanavati, 491 Sushma Nangia, Paul Newton, Chanpheaktra Ngoun, Amanda Novotney, Davis Nwakanma, 492 Christina W. Obiero, Antonio Olivas-Martinez, Piero Olliaro, Ednah Ooko, Edgar Ortiz-493 Brizuela, Anton Yariv Peleg, Carlo Perrone, Nishad Plakkal, Alfredo Ponce-de Leon, Math-494 ieu Raad, Tanusha Ramdin, Amy Riddell, Tamalee Roberts, Julie Victoria Robotham, 495 Anna Roca, Kristina E. Rudd, Neal Russell, Jesse Schnall, John Anthony Gerard Scott, 496 Madhusudhan Shivamallappa, Jose Sifuentes-Osornio, Nicolas Steenkeste, Andrew James 497 Stewardson, Temenuga Stoeva, Nidanuch Tasak, Areerat Thaiprakong, Guy Thwaites, 498 Claudia Turner, Paul Turner, H. Rogier van Doorn, Sithembiso Velaphi, Avina Vongpra-499 dith, Huong Vu, Timothy Walsh, Seymour Waner, Tri Wangrangsimakul, Teresa Wozniak, 500 Peng Zheng, Benn Sartorius, Alan D. Lopez, Andy Stergachis, Catrin Moore, Christiane 501 Dolecek, and Mohsen Naghavi. Global burden of bacterial antimicrobial resistance in 2019: 502 a systematic analysis. The Lancet, 399(10325):629–655, February 2022. ISSN 0140-6736, 503 1474-547X. doi: 10.1016/S0140-6736(21)02724-0. URL https://www.thelancet.com/ 504 journals/lancet/article/PIIS0140-6736(21)02724-0/fulltext. Publisher: Elsevier. 505
- [2] Christopher Witzany, Sebastian Bonhoeffer, and Jens Rolff. Is antimicrobial resistance
   evolution accelerating? *PLOS Pathogens*, 16(10):e1008905, October 2020. ISSN 1553-7374.
   doi: 10.1371/journal.ppat.1008905. URL https://journals.plos.org/plospathogens/
   article?id=10.1371/journal.ppat.1008905. Publisher: Public Library of Science.
- [3] Althea W McCormick, Cynthia G Whitney, Monica M Farley, Ruth Lynfield, Lee H Harrison, Nancy M Bennett, William Schaffner, Arthur Reingold, James Hadler, Paul Cieslak, et al. Geographic diversity and temporal trends of antimicrobial resistance in streptococcus pneumoniae in the united states. *Nature medicine*, 9(4):424–430, 2003.
- [4] L. Clifford McDonald. Trends in Antimicrobial Resistance in Health Care-Associated Pathogens and Effect on Treatment. *Clinical Infectious Diseases*, 42(Supplement\_2):S65-S71, January 2006. ISSN 1058-4838. doi: 10.1086/499404. URL https://doi.org/10. 1086/499404.
- [5] Lotta Siira, Merja Rantala, Jari Jalava, Antti J. Hakanen, Pentti Huovinen, Tarja Kaijalainen, Outi Lyytikäinen, and Anni Virolainen. Temporal trends of antimicrobial resistance and clonality of invasive Streptococcus pneumoniae isolates in Finland, 2002 to 2006.
   Antimicrobial Agents and Chemotherapy, 53(5):2066–2073, May 2009. ISSN 1098-6596. doi: 10.1128/AAC.01464-08.
- [6] A. Fenoll, J. J. Granizo, L. Aguilar, M. J. Giménez, L. Aragoneses-Fenoll, G. Hanquet,
   J. Casal, and D. Tarragó. Temporal trends of invasive Streptococcus pneumoniae serotypes
   and antimicrobial resistance patterns in Spain from 1979 to 2007. *Journal of Clinical Microbiology*, 47(4):1012–1020, April 2009. ISSN 1098-660X. doi: 10.1128/JCM.01454-08.

#### perpetuity. It is made available under a CC-BY-NC 4.0 International license .

- [7] Majdi N Al-Hasan, Brian D Lahr, Jeanette E Eckel-Passow, and Larry M Baddour. Antimicrobial resistance trends of escherichia coli bloodstream isolates: a population-based study, 1998–2007. Journal of antimicrobial chemotherapy, 64(1):169–174, 2009.
- [8] Robert D Kirkcaldy, Sarah Kidd, Hillard S Weinstock, John R Papp, and Gail A Bolan.
   Trends in antimicrobial resistance in neisseria gonorrhoeae in the usa: the gonococcal isolate
   surveillance project (gisp), january 2006–june 2012. Sexually transmitted infections, 89
   (Suppl 4):iv5–iv10, 2013.
- [9] F.-P. Hu, Y. Guo, D.-M. Zhu, F. Wang, X.-F. Jiang, Y.-C. Xu, X.-J. Zhang, C.-X. Zhang, 534 P. Ji, Y. Xie, M. Kang, C.-Q. Wang, A.-M. Wang, Y.-H. Xu, J.-L. Shen, Z.-Y. Sun, Z.-535 J. Chen, Y.-X. Ni, J.-Y. Sun, Y.-Z. Chu, S.-F. Tian, Z.-D. Hu, J. Li, Y.-S. Yu, J. Lin, 536 B. Shan, Y. Du, Y. Han, S. Guo, L.-H. Wei, L. Wu, H. Zhang, J. Kong, Y.-J. Hu, X.-M. Ai, 537 C. Zhuo, D.-H. Su, Q. Yang, B. Jia, and W. Huang. Resistance trends among clinical isolates 538 in China reported from CHINET surveillance of bacterial resistance, 2005-2014. Clinical 539 Microbiology and Infection: The Official Publication of the European Society of Clinical 540 Microbiology and Infectious Diseases, 22 Suppl 1:S9-14, March 2016. ISSN 1469-0691. doi: 541 10.1016/j.cmi.2016.01.001. 542
- [10] Dee Shortridge, Ana C. Gales, Jennifer M. Streit, Michael D. Huband, Athanasios Tsakris,
  and Ronald N. Jones. Geographic and Temporal Patterns of Antimicrobial Resistance
  in Pseudomonas aeruginosa Over 20 Years From the SENTRY Antimicrobial Surveillance
  Program, 1997-2016. Open Forum Infectious Diseases, 6(Suppl 1):S63–S68, March 2019.
  ISSN 2328-8957. doi: 10.1093/ofid/ofy343.
- [11] Jean Carlet, Vincent Jarlier, Jacques Acar, Olivier Debaere, Patrick Dehaumont, Bruno
  Grandbastien, Pierre Le Coz, Gerard Lina, Yves Pean, Claude Rambaud, France Roblot,
  Jérôme Salomon, Benoit Schlemmer, Pierre Tattevin, and Benoit Vallet. Trends in Antibiotic Consumption and Resistance in France Over 20 Years: Large and Continuous Efforts
  but Contrasting Results. *Open Forum Infectious Diseases*, 7(11):ofaa452, November 2020.
  ISSN 2328-8957. doi: 10.1093/ofid/ofaa452.
- [12] Rik Oldenkamp, Constance Schultsz, Emiliano Mancini, and Antonio Cappuccio. Filling
   the gaps in the global prevalence map of clinical antimicrobial resistance. Proceedings of
   the National Academy of Sciences, 118(1):e2013515118, 2021.
- [13] Shirin Aliabadi, Elita Jauneikaite, Berit Müller-Pebody, Russell Hope, Karina-Doris Vihta, Carolyne Horner, and Céire E. Costelloe. Exploring temporal trends and risk factors for resistance in Escherichia coli-causing bacteraemia in England between 2013 and 2018: an ecological study. *The Journal of Antimicrobial Chemotherapy*, 77(3):782–792, February 2022. ISSN 1460-2091. doi: 10.1093/jac/dkab440.
- [14] European Centre for Disease Prevention, Control, and World Health Organization. Antimi crobial resistance surveillance in europe 2023 2021 data. *Stockholm*, 2023.
- [15] Eve Rahbe, Laurence Watier, Didier Guillemot, Philippe Glaser, and Lulla Opatowski.
   Determinants of worldwide antibiotic resistance dynamics across drug-bacterium pairs: a
   multivariable spatial-temporal analysis using atlas. The Lancet Planetary Health, 7(7):
   e547–e557, 2023.
- [16] Marc Lipsitch. The rise and fall of antimicrobial resistance. Trends in Microbiology, 9(9):
   438-444, September 2001. ISSN 0966-842X. doi: 10.1016/S0966-842X(01)02130-8. URL
   https://www.sciencedirect.com/science/article/pii/S0966842X01021308.
- [17] Caroline Colijn, Ted Cohen, Christophe Fraser, William Hanage, Edward Goldstein, Noga Givon-Lavi, Ron Dagan, and Marc Lipsitch. What is the mechanism for persistent coexistence of drug-susceptible and drug-resistant strains of Streptococcus pneumoniae? Journal of The Royal Society Interface, 7(47):905–919, June 2010. doi: 10.1098/ rsif.2009.0400. URL https://royalsocietypublishing.org/doi/full/10.1098/rsif.
  2009.0400. Publisher: Royal Society.
- <sup>577</sup> [18] François Blanquart, Sonja Lehtinen, Marc Lipsitch, and Christophe Fraser. The evolution of antibiotic resistance in a structured host population. *Journal of The Royal Society Interface*, 15(143):20180040, June 2018. doi: 10.1098/rsif.2018.0040. URL https: //royalsocietypublishing.org/doi/full/10.1098/rsif.2018.0040. Publisher: Royal Society.

perpetuity. It is made available under a CC-BY-NC 4.0 International license .

 [19] Madison S. Krieger, Carson E. Denison, Thayer L. Anderson, Martin A. Nowak, and Alison L. Hill. Population structure across scales facilitates coexistence and spatial heterogeneity of antibiotic-resistant infections. *PLOS Computational Biology*, 16(7):e1008010, July
 2020. ISSN 1553-7358. doi: 10.1371/journal.pcbi.1008010. URL https://journals.plos.
 org/ploscompbiol/article?id=10.1371/journal.pcbi.1008010. Publisher: Public Library of Science.

 [20] Sonja Lehtinen, François Blanquart, Nicholas J. Croucher, Paul Turner, Marc Lipsitch, and Christophe Fraser. Evolution of antibiotic resistance is linked to any genetic mechanism affecting bacterial duration of carriage. *Proceedings of the National Academy of Sciences*, 114 (5):1075–1080, January 2017. ISSN 0027-8424, 1091-6490. doi: 10.1073/pnas.1617849114.
 URL https://www.pnas.org/content/114/5/1075. Publisher: National Academy of Sciences.

- [21] Nicholas G. Davies, Stefan Flasche, Mark Jit, and Katherine E. Atkins. Within-host dynamics shape antibiotic resistance in commensal bacteria. Nature Ecology & Evolution, 3(3):440-449, March 2019. ISSN 2397-334X. doi: 10.1038/s41559-018-0786-x. URL https://www.nature.com/articles/s41559-018-0786-x. Number: 3 Publisher: Nature Publishing Group.
- [22] Herman Goossens, Matus Ferech, Robert Vander Stichele, Monique Elseviers, and ESAC
   Project Group. Outpatient antibiotic use in Europe and association with resistance: a
   cross-national database study. *Lancet (London, England)*, 365(9459):579–587, February
   2005. ISSN 1474-547X. doi: 10.1016/S0140-6736(05)17907-0.
- [23] Scott W Olesen, Michael L Barnett, Derek R MacFadden, John S Brownstein, Sonia
   Hernández-Díaz, Marc Lipsitch, and Yonatan H Grad. The distribution of antibiotic use and
   its association with antibiotic resistance. *eLife*, 7:e39435, December 2018. ISSN 2050-084X.
   doi: 10.7554/eLife.39435. URL https://doi.org/10.7554/eLife.39435. Publisher: eLife
   Sciences Publications, Ltd.
- [24] François Blanquart and Sylvain Gandon. Time-shift experiments and patterns of adaptation across time and space. *Ecology letters*, 16(1):31–38, 2013.
- <sup>610</sup> [25] Paul-Louis Woerther, Charles Burdet, Elisabeth Chachaty, and Antoine Andremont. Trends <sup>611</sup> in human fecal carriage of extended-spectrum  $\beta$ -lactamases in the community: toward the <sup>612</sup> globalization of ctx-m. *Clinical microbiology reviews*, 26(4):744–758, 2013.
- <sup>613</sup> [26] Scott W Olesen, Marc Lipsitch, and Yonatan H Grad. The role of "spillover" in antibiotic <sup>614</sup> resistance. *Proceedings of the National Academy of Sciences*, 117(46):29063–29068, 2020.
- [27] Sonja Lehtinen, François Blanquart, Marc Lipsitch, Christophe Fraser, and with the Maela
   Pneumococcal Collaboration. On the evolutionary ecology of multidrug resistance in bacteria. *PLoS pathogens*, 15(5):e1007763, 2019.
- [28] Peter Collignon, John J Beggs, Timothy R Walsh, Sumanth Gandra, and Ramanan Laxmi narayan. Anthropological and socioeconomic factors contributing to global antimicrobial
   resistance: a univariate and multivariable analysis. *The Lancet Planetary Health*, 2(9):
   e398–e405, 2018.
- [29] Zhenchao Zhou, Xinyi Shuai, Zejun Lin, Xi Yu, Xiaoliang Ba, Mark A Holmes, Yonghong Xiao, Baojing Gu, and Hong Chen. Association between particulate matter (pm) 2. 5 air pollution and clinical antibiotic resistance: a global analysis. *The Lancet Planetary Health*, 7(8):e649–e659, 2023.
- [30] C Slekovec, J Robert, Denis Trystram, JM Delarbre, A Merens, N van Der Mee-Marquet,
   C de Gialluly, Y Costa, J Caillon, D Hocquet, et al. Pseudomonas aeruginosa in french
   hospitals between 2001 and 2011: back to susceptibility. European journal of clinical mi crobiology & infectious diseases, 33:1713–1717, 2014.
- [31] ECDC. TESSy-The European Surveillance System Antimicrobial resistance (AMR) report ing protocol 2021 European Antimicrobial Resistance Surveillance Network (EARS-Net)
   surveillance data for 2020. (February):38, 2021. URL https://www.ecdc.europa.eu/
   sites/default/files/documents/EARS-Net-reporting-protocol-2021\_v2.pdf.

medRxiv preprint doi: https://doi.org/10.1101/2023.09.27.23296241; this version posted September 28, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

[32] ECDC. TESSy -The European Surveillance System Antimicrobial consumption (AMC) 634 reporting protocol 2022 European Surveillance of Antimicrobial Consumption Network 635 (ESAC-Net) surveillance data for 2022. (March), 2022. URL https://www.ecdc.europa. 636 eu/sites/default/files/documents/ESACNet\_protocol\_2022.pdf. 637

[33] Timur V Elzhov, Katharine M Mullen, Andrej-Nikolai Spiess, and Ben Bolker Maintainer. 638 minpack.lm: R Interface to the Levenberg-Marquardt Nonlinear Least-Squares Algorithm 639 Found in MINPACK, Plus Support for Bounds. R package version 1.2-1, pages 1–14, 2016. 640 URL https://cran.r-project.org/web/packages/minpack.lm/minpack.lm.pdf. 641

- [34] R Core Team. R: A Language and Environment for Statistical Computing. R Foundation 642 for Statistical Computing, Vienna, Austria, 2022. URL https://www.R-project.org/. 643
- [35] Kenneth P Burnham and David R Anderson. Multimodel inference: understanding aic and 644 bic in model selection. Sociological methods & research, 33(2):261–304, 2004. 645
- [36] Andri Signorell, Ken Aho, Andreas Alfons, Nanina Anderegg, Tomas Aragon, Antti Arppe, 646 Adrian Baddeley, Kamil Barton, Ben Bolker, Hans W Borchers, et al. Desctools: Tools for 647 descriptive statistics. R package version 0.99, 28:17, 2019. 648
- [37] Kevin Ushey. renv: Project Environments, 2023. URL https://CRAN.R-project.org/ 649 package=renv. R package version 0.17.3. 650